Delving into the Latest Updates on Vandetanib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, Vandetanib (JAN/USAN/INN)

+ [18]

Target

BRK x Eph x RET x Tie-2

Action

inhibitors, antagonists

Mechanism

BRK inhibitors(Tyrosine-protein kinase BRK inhibitors), Eph inhibitors(Ephrin receptor inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseOther Diseases+ [1]

Active Indication

RET Mutation-Positive Medullary Thyroid CancerAdvanced Thyroid Gland Medullary CarcinomaMetastatic Thyroid Gland Medullary Carcinoma+ [3]

Inactive Indication

Advanced biliary tract cancerAdvanced breast cancerAdvanced Colorectal Adenocarcinoma+ [59]

Originator Organization

AstraZeneca Pharmaceuticals Co. Ltd.

Active Organization

Sanofi-Aventis Korea Co., Ltd.

Genzyme Corp.AstraZeneca AB

+ [6]

Inactive Organization

Celgene Corp.

AstraZeneca PLC

Dana-Farber Cancer Institute, Inc.

License Organization

AstraZeneca PLC

Esteve Pharmaceuticals SA

Genzyme Corp.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (06 Apr 2011),

Thyroid Cancer, Medullary

RegulationOrphan Drug (United States), Orphan Drug (South Korea), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H24BrFN4O2

InChIKeyUHTHHESEBZOYNR-UHFFFAOYSA-N

CAS Registry443913-73-3

Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI).
The purpose of this study is to evaluate the efficacy and tolerability of tyrosine kinase inhibitor therapy (Lenvatinib or Sorafenib for differentiated thyroid cancer [which includes papillary thyroid cancer, follicular thyroid cancer, and poorly differentiated thyroid cancer]; and Cabozantinib or Vandetanib for medullary thyroid cancer) through adaptive (intermittent) versus conventional (continuous) regimen.

Start Date06 Aug 2018

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

EUCTR2017-002517-64-GB

/ Not yet recruitingPhase 1/2

An open label, single-arm, Phase I/II study of vandetanib-eluting radiopaque embolic beads (BTG-002814) in patients with hepatocellular carcinoma (HCC) without curative options - VALENCIA

Start Date15 Dec 2017

Sponsor / Collaborator

Biocompatibles UK Ltd.

100 Clinical Results associated with Vandetanib

Login to view more data

100 Translational Medicine associated with Vandetanib

Login to view more data

100 Patents (Medical) associated with Vandetanib

Login to view more data

1,565

Literatures (Medical) associated with Vandetanib

31 Dec 2025·Virulence

Ponatinib and other clinically approved inhibitors of Src and Rho-A kinases abrogate dengue virus serotype 2- induced endothelial permeability

Article

Author: Awasthi, Mansi ; Modak, Ayan ; Sobha, Archana ; Sreekumar, Easwaran ; Mishra, Srishti Rajkumar

Severe dengue often presents as shock syndrome with enhanced vascular permeability and plasma leakage into tissue spaces. In vitro studies have documented the role of Src family kinases (SFKs) and RhoA-kinases (ROCK) in dengue virus serotype 2 (DENV2)-induced endothelial permeability. Here, we show that the FDA-approved SFK inhibitors Bosutinib, Vandetanib and Ponatinib, as well as the ROCK inhibitors, Netarsudil and Ripasudil significantly inhibit DENV2-induced endothelial permeability. In cultured telomerase immortalized human microvascular endothelial cells (HMEC-1), treatment with these inhibitors reduced the phosphorylation of VE-Cadherin, Src and myosin light chain 2 (MLC2) proteins that were upregulated during DENV2 infection. It also prevented the loss of VE-Cadherin from the inter-endothelial cell junctions induced by viral infection. In in-vivo studies using DENV2-infected AG129 IFN receptor-α/β/γ deficient mice, ponatinib, when administered 24 h post-infection onwards, demonstrated significant benefits in improving body weight, clinical outcomes, and survival rates. While all virus-infected, untreated mice died by day-10 post-infection, 80% of the ponatinib-treated mice survived, and approximately 60% were still alive at the end of the 15-day observation period. The treatment also significantly reduced disease severity factors such as vascular leakage, thrombocytopenia; mRNA transcript levels of proinflammatory cytokines such as IL-1β and TNF-α; and restored liver function. Comparable effects were observed even when ponatinib treatment was initiated after symptom onset. The results highlight ponatinib as an effective therapeutic option in severe dengue; and also a similar potential for other FDA- approved SFK and ROCK inhibitors.

01 Nov 2025·PHARMACOLOGICAL RESEARCH

Vascular endothelial cells and angiogenesis

Review

Author: Roskoski, Robert

Physiological vascular endothelial cell division and angiogenesis occur during embryonic development, wound healing, in the endometrium during the menstrual cycle, and during placental development. Otherwise, vascular endothelial cells divide less than once per decade. Neoplasms are limited in size (∼ 1.0 mm) owing to a deficiency of oxygen and metabolic fuels. To grow larger, new blood vessels form from pre-existing vasculature by angiogenesis (capillary sprouting). During this process, mature endothelial cells replicate and become incorporated into new capillaries resulting in tumor growth. Angiogenesis results in part from the increased production of vascular endothelial growth factors (VEGFs). The human VEGF family consists of VEGF-A/B/C/D and placental growth factor (PlGF). The VEGF family of receptors consists of three protein-tyrosine kinases (VEGFR1/2/3) and two nonprotein kinase receptors (neuropilin-1 and neuropilin-2). Semaphorins 3A-F/4A-G/5 A/B/6A-G/7 A are regulatory ligands that interact with their neuropilin and plexin receptors (PlxA1-A4/B1-B3/C1/D1) and regulate angiogenesis. Angiopoietin-1/2/4 interact with their Tie1/2 receptor protein-tyrosine kinases to modulate vasculogenesis and angiogenesis. Ephrin ligands (EfnA1/A2/A3/A4/A5/B1/B2/B3) and Ephrin receptors (EphA1/A2/A3/A4/A5/A6/A7/A8/A10/B1/B2/B3/B4/B6/) also contribute to angiogenesis. Platelet-derived growth factors, fibroblast growth factors, hepatocyte growth factor (c-Met), stem cell growth factor (Kit) receptor protein-tyrosine kinases, PKB/Akt, Src, and MAP kinases also participate in angiogenesis. Owing to its importance in tumor progression, the inhibition of angiogenic signaling represents an attractive cancer treatment. Ponatinib, regorafenib, and vandetanib are FDA-approved VEGFR, Tie2, and Ephrin receptor blockers used in the treatment of various malignancies. Other disorders characterized by aberrant angiogenesis include diabetic retinopathies and neovascular age-related macular degeneration.

01 Nov 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy

Article

Author: Abad-Santos, Francisco ; Frade-Porto, Natalia ; Maietta, Paolo ; Torres-Díaz, Cristina Virginia ; Ovejero-Benito, María C ; Granero-Cremades, Inmaculada ; Elizalde-Horcada, Marcos ; Sánchez-Jiménez, Patricia ; de Toledo, Maria ; Pulido, Paloma ; Gómez-Martín, Antonio ; Cerrada-Gálvez, Laura ; Gonzalez-Tarno, Patricia ; Alonso-Guirado, Lola

BACKGROUND:

Epilepsy drug treatments fail in 25-30 % of patients, leading to drug resistance. Temporal lobe epilepsy is the most prevalent subtype associated with drug resistance. Classical drug discovery is a long and extremely costly process with a high failure rate in clinical trials. Drug repurposing is a more cost- and time-effective strategy. Hence, the main objective of this study is to propose drug candidates for the treatment of drug-resistant temporal lobe epilepsy (DR-TLE) through drug repurposing based on transcriptomic profiling.

METHODS:

Total RNA-sequencing (RNA-Seq) was performed on 45 formalin-fixed paraffin-embedded (FFPE) hippocampi of DR-TLE patients and 36 FFPE hippocampi of post-mortem biobank donors. RNA-Seq was carried out on an Illumina NovaSeq 6000 platform in 100bp paired-end. Drug repurposing based on transcriptomic analysis top candidates was performed against these databases: Pandrugs2, PharmOmics, DGIdb, ToppGene, L1000CDS² and Connectivity Map.

RESULTS:

We identified 887 genes differentially expressed between DR-TLE patients and post-mortem controls. We observed 74 potential drug candidates in at least two independent databases. Of these, we selected only the 11 which can cross the blood-brain barrier: cobimetinib, panobinostat, melphalan, rucaparib, alectinib, ponatinib, danazol, carboplatin, vandetanib, erlotinib, and gefitinib. After analyzing their mechanisms to modulate epileptogenesis, their safety and efficacy profiles from previous publications, we provide a list of the top 5 candidates.

CONCLUSION:

Based on differential RNA-Seq profiling, we therefore propose erlotinib, danazol, rucaparib, ponatinib, and panobinostat.

23

News (Medical) associated with Vandetanib

25 Sep 2025

·www.einpresswire.com

FDA Removes Risk Evaluation and Mitigation Strategies (REMS) for Caprelsa (vandetanib)

FDA News Release Agency determines special restrictions are no longer necessary to ensure the benefits of thyroid cancer treatment with Caprelsa outweigh its risks For Immediate Release: September 25, 2025 The U.S. Food and Drug Administration today removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Genzyme Corporation (now Sanofi). The FDA first approved Caprelsa in 2011 to treat medullary thyroid cancer in patients whose disease has spread or cannot be surgically removed. At the time, a REMS program was required to ensure appropriate heart rhythm monitoring and safe use. After over more than a decade of oversight, REMS assessments reported no cases of Torsades de pointes or unexplained sudden deaths among U.S. patients taking Caprelsa. Clinical data also showed no concerning patterns of heart rhythm problems. “Cancer specialists now have adequate knowledge about managing the heart rhythm related risks of this medication,” said Richard Pazdur, M.D., FDA Oncology Center of Excellence Director . “Health care providers have incorporated proper safety monitoring into their standard practice, making the formal requirements unnecessary. The mandatory monitoring program has achieved its goals.” Caprelsa will remain available with the same prescribing information, but health care providers will no longer need special certification or extra monitoring beyond standard clinical care. A REMS is a safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. The safety requirements for Caprelsa included mandatory training for health care providers and monitoring of patients. Contact Information: Health care providers, pharmacies, and patients with questions may contact the FDA at (855) 543-3784 or (301) 796-3400, or by email at druginfo@fda.hhs.gov . Adverse events, medication errors, or quality problems with Caprelsa should be reported to FDA's MedWatch Adverse Event Reporting program. FDA's top priority is patient safety, and the agency will continue to monitor the safety of this medication. ### Boilerplate The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

30 Jun 2025

·www.prnewswire.com

ESTEVE to acquire medicine to treat medullary thyroid cancer

Caprelsa® (vandetanib) is a medicine that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer1. This is a new step forward in ESTEVE's international growth journey focused on highly specialized treatments for high unmet medical and patient needs.  BARCELONA, Spain, June 30, 2025 /PRNewswire/ -- ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries, a treatment that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer1. Medullary thyroid carcinoma is a type of cancer that starts in the cells in the thyroid gland that produces the hormone calcitonin. This product is a 'protein tyrosine kinase inhibitor' that blocks the activity of enzymes known as tyrosine kinase. Consequently, the medicine reduces the blood supply to the cancer cells, slowing down the cancer's growth1. "Medullary thyroid carcinoma is a rare neuroendocrine tumor that can produce calcitonin from parafollicular cells. The primary treatment is surgery. However, treatments like vandetanib can often slow down or even partially reverse the tumour growth2. We at ESTEVE are proud to join the fighting effort of the patients diagnosed with this carcinoma and their healthcare professionals, with the ambition to continue improving patient's health and lives", confirms José María Giménez-Arnau, Chief Scientific & Medical Officer of ESTEVE.  In April 2024, ESTEVE acquired a business specialized in rare and ultra-rare diseases in the areas of endocrinology and onco-endocrinology, as a step forward towards becoming a highly specialized company. This acquisition added three new medicines to its portfolio addressing endogenous Cushing's syndrome and Adrenocortical Carcinoma.   Furthermore, last month, ESTEVE acquired a license for a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency3. Building on this, the company last month, the company secured an adjuvant therapy considered the standard of care for high-grade, resectable, non-metastatic osteosarcoma in patients between 2 and 30 years of age4. "We are proud to confirm that we are increasing our highly specialized therapies portfolio. Caprelsa® will help us to improve the lives of patients all around the world. This is a step forward in ESTEVE's international journey focused on highly specialized treatments for high unmet medical needs of patients", concludes Jacob Tolstrup, Chief Commercial Officer of ESTEVE. [The completion of the transaction is subject to obtaining customary regulatory clearances]. References Caprelsa | European Medicines Agency (EMA) Medullary Thyroid Cancer | American Thyroid Association Increlex | European Medicines Agency (EMA)   Mepact I European Medicines Agency (EMA) About ESTEVE ESTEVE () is a global pharmaceutical company with a clear purpose: to improve people's lives. Founded in 1929 and headquartered in Barcelona, ESTEVE has a strong international presence with pharmaceutical affiliates in Spain, Portugal, Italy, Germany, France, the UK, and the USA.   ESTEVE is focused on delivering highly specialized treatments that address significant unmet medical needs in several therapeutic areas. In addition, to our innovative pharma business, we offer comprehensive Contract Manufacturing services (CMO), specializing in the production of Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, and China.  ESTEVE's strong commitment to its core values—people matter, transparency, and accountability—remains at the heart of everything it does.  For more information: Irene Simón, Head of Global External Communications & ESG, ESTEVE Tel.+34 934 466 000 – [email protected] Gemma Mestre, External & Digital Communications Manager, ESTEVE Tel.+34 934 466 000 – [email protected] Logo - SOURCE ESTEVE WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionLicense out/in

30 Sep 2024

·www.fda.gov

FDA approves selpercatinib for medullary thyroid cancer with a RET mutation

On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. Selpercatinib received accelerated approval for this indication for patients 12 years of age and older in 2020. On May 29, 2024, the FDA granted accelerated approval for this indication to pediatric patients 2 years of age and older. Efficacy was evaluated in LIBRETTO-531 (NCT04211337), a randomized, multicenter, open-label study in adults and adolescents with advanced or metastatic RET-mutant MTC. Patients were randomized (2:1) to receive either selpercatinib (160 mg twice daily) or physicians’ choice of cabozantinib (140 mg once daily) or vandetanib (300 mg once daily). Patients were stratified based on RET mutation (M918T vs. other) and intended treatment if randomized to the control arm (cabozantinib vs. vandetanib). The main efficacy outcome measure was progression-free survival (PFS), as determined by a blinded independent review committee according to RECIST v1.1. Median PFS was not reached (NR) (95% CI: not evaluable [NE], NE) in the selpercatinib arm and 16.8 months (95% CI: 12.2, 25.1) in the cabozantinib/vandetanib arm (Hazard Ratio 0.280 [95% CI: 0.165, 0.475] p-value <0.0001). The clinical benefit of selpercatinib was supported by a pre-specified analysis of patient-reported comparative side effect impact; patients in the selpercatinib arm reported less time with severe side effect bother than those receiving cabozantinib or vandetanib. The most common adverse reactions (≥25%) were hypertension, edema, dry mouth, fatigue, and diarrhea. The most common Grade 3 or 4 laboratory abnormalities (≥5%) were decreased lymphocytes, increased alanine aminotransferase (ALT), decreased neutrophils, increased alkaline phosphatase (ALP), increased blood creatinine, decreased calcium, and increased aspartate aminotransferase (AST). The recommended selpercatinib dose for pediatric patients 2 to less than 12 years of age is based on body surface area and is based on weight for patients 12 years of age and older. See the prescribing information for specific dosing information. Expedited Programs This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was granted priority review, breakthrough designation, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X: @FDAOncologyExternal Link Disclaimer. Content current as of: 09/30/2024 Regulated Product(s) Drugs Content current as of: 09/30/2024 Regulated Product(s) Drugs Resources for Information | Approved Drugs Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description

Drug ApprovalPriority ReviewAccelerated ApprovalOrphan DrugClinical Result

100 Deals associated with Vandetanib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06407	Vandetanib	L01XE12	DB05294

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
RET Mutation-Positive Medullary Thyroid Cancer	European Union	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	Iceland	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	Liechtenstein	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	Norway	Sanofi	01 Feb 2023
Advanced Thyroid Gland Medullary Carcinoma	South Korea	Sanofi-Aventis Korea Co., Ltd.	24 May 2013
Metastatic Thyroid Gland Medullary Carcinoma	South Korea	Sanofi-Aventis Korea Co., Ltd.	24 May 2013
Thyroid Cancer, Medullary	United States	Genzyme Corp.	06 Apr 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	IPR Pharmaceuticals, Inc.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	AstraZeneca AB	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	AstraZeneca Pharmaceuticals Co. Ltd.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	China	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	AstraZeneca Pharmaceuticals Co. Ltd.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	IPR Pharmaceuticals, Inc.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	AstraZeneca AB	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Brazil	Genzyme Corp.	17 Sep 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03291379 (VEROnA, Pubmed) Manual	Phase 1	Neoplasms	8	Vandetanib-Eluting Radiopaque Embolics	yjbglonhmf(mtxtuzapmu) = There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. oncndikllb (iligzfqklu )	Positive	05 May 2022
NCT01934335 (CTgov)	Phase 2	Invasive Mammary Carcinoma	12	Vandetanib (Vandetanib)	ybrylkqato(aiuprdqxjh) = ysysfjhnpv gevqatoaex (uknbbarxaf, 0.08) View more	-	01 Nov 2021
				Placebo (Placebo)	ybrylkqato(aiuprdqxjh) = mbiawkbcgx gevqatoaex (uknbbarxaf, 0.05) View more
NCT01586624 (CTgov)	Phase 1	Non-Small Cell Lung Cancer	61	Selumetinib+Vandetanib (Dose Escalation Phase Cohort 1 (Steady State Dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib))	whclnamtou = vceoosxrgv wjpsguuiaa (qhtnurchie, tdullmiszj - tlkuycmoqz) View more	-	07 Oct 2021
				Selumetinib+Vandetanib (Dose Escalation Phase Cohort 2 (Steady State Dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib))	whclnamtou = edzrxsdmut wjpsguuiaa (qhtnurchie, zwunatlszz - rsdewtgrzp) View more
NCT01582191 (Pubmed \| ESMO Open) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	80	vandetanib+everolimus	jmyvvinbpp(gakpegyxpd) = jsnuhadbei fmbgbbsqzg (jgoizbjfan, 3.4 - 7.3) View more	Positive	01 Apr 2021
NCT03291379 (VEROnA, CTgov)	Early Phase 1	Hepatocellular Carcinoma \| Metastatic Colorectal Carcinoma	8	BTG-002814	gouiuyjeku = ypbfrgfyhp ckmhcgcxrt (bpzsloetjl, uqckzymexc - qbzmpviyss) View more	-	03 Feb 2021
NCT03630120 (CTgov)	Phase 2	Thyroid Cancer, Follicular \| Differentiated Thyroid Gland Carcinoma \| Papillary thyroid cancer ... View more	6	Sorafenib+Lenvatinib (Standard of Care: DTC)	qvgefycviw(orijnalnqw) = fmdzmkcexm suxwdvgqjd (ixrvkwqawv, atsnjwwqbc - wlxhprgmdi) View more	-	22 Jan 2021
				Sorafenib+Lenvatinib (Adaptive Care: DTC)	qvgefycviw(orijnalnqw) = nmqnfyhsmh suxwdvgqjd (ixrvkwqawv, jbqimotxph - vykfwjqomt) View more
NCT01183559 (CTgov)	Phase 1	Esophageal Carcinoma \| Locally Advanced Gastroesophageal Junction Adenocarcinoma	9	External Beam Radiation Therapy (RT)+Carboplatin+Vandetanib+Paclitaxel+FU	rpscmbpcav = spgjwjurxb blyrtjofnu (unjygucrsr, jrpogflctl - usarbdsvfc) View more	-	22 Jan 2021
NCT01414426 (CTgov)	Phase 2	Squamous cell carcinoma of the oral cavity \| Verrucous Carcinoma \| Precancerous Conditions	20	biopsy+vandetanib (Arm I (Chemoprevention))	ghkhqgxljk = mheanwknnt lciwvragbv (mmcmmhbjur, fpphdafwtj - ykmrglxqws) View more	-	14 Jan 2021
				placebo (Arm II (Placebo))	ghkhqgxljk = fupouzmzco lciwvragbv (mmcmmhbjur, nmahcfgusv - narghdaefd) View more
NCT00514046 (CTgov)	Phase 1/2	Familial Medullary Thyroid Carcinoma \| Multiple Endocrine Neoplasia Type 2b \| Thyroid Cancer, Medullary	17	Vandetanib (All Participants)	dlklzkvsyu = fnflxfbali lpqdjzsori (ljtgakwkll, zogoalbtki - wpbjhplfil) View more	-	22 Dec 2020
				Vandetanib (Vandetanib: First 100 mg/m^2, Then 150 mg/m^2)	chcsdtjchx = sbrytgzwvs slryznlpci (czgtfgfqpo, nlwhzvbgkn - qnvrwafjsz) View more
NCT02530411 (FURVA, ESMO2020)	Phase 2	Estrogen receptor positive breast cancer	165	Vandetanib 300mg + Fulvestrant 500mg	slmyphdgqe(fwqbdkryyi) = ejdjtpdwrv ynnuoiwnwc (sbhxtwqjtt ) View more	Negative	18 Sep 2020
				Placebo + Fulvestrant 500mg	slmyphdgqe(fwqbdkryyi) = mpgkoahwqd ynnuoiwnwc (sbhxtwqjtt ) View more